PMID- 26218502
OWN - NLM
STAT- MEDLINE
DCOM- 20180319
LR  - 20181202
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 20
IP  - 1
DP  - 2017 Jan
TI  - No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort 
      of patients with systemic sclerosis-associated pulmonary arterial hypertension on 
      therapy with bosentan.
PG  - 90-96
LID - 10.1111/1756-185X.12721 [doi]
AB  - AIM: The aim of this study was to evaluate N-terminal pro-brain natriuretic 
      peptide (NT-proBNP) in patients with systemic sclerosis (SSc)-associated 
      pulmonary arterial hypertension (PAH) and changes after therapy with bosentan. 
      METHOD: Twenty-one patients with SSc-PAH on bosentan therapy were enrolled. PAH 
      was diagnosed by right heart catheterization. NT-proBNP levels, 6-min walking 
      test (6MWT), Doppler echocardiography to estimated systolic pulmonary arterial 
      pressure (sPAP), New York Heart Association (NYHA) functional class for dyspnea 
      and carbon monoxide lung diffusion capacity (DLco) were recorded at baseline, and 
      after 1 and 2 years. Fifty-two SSc patients without PAH were also evaluated as 
      controls. RESULTS: NT-proBNP plasma levels were significantly higher in SSc-PAH 
      at 385 pg/mL (SD +/- 427) than in SSc without PAH and 72 pg/mL (SD +/- 52, P < 0.001) 
      at baseline, but did not significantly change following bosentan therapy at 
      1 year (330 pg/mL [SD +/- 291] and 2 years (374 pg/mL [SD +/- 291]). However, NYHA 
      class significantly improved at 2 years (P = 0.01) as well as 6MWT (P = 0.04). 
      NT-proBNP levels were positively correlated only with sPAP but not with DLco, 
      NYHA class or 6MWT. CONCLUSIONS: NT-proBNP levels were found to be significantly 
      higher in SSc-PAH at baseline. Serial assessment of NT-proBNP in SSc-PAH patients 
      on bosentan therapy showed no relation to the clinical improvement. This suggests 
      that NT-proBNP may lack 'sensitivity to change', but further studies are 
      warranted to assess the role of NT-proBNP as a biomarker of the therapeutic 
      response in larger cohorts of SSc patients.
CI  - (c) 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing 
      Asia Pty Ltd.
FAU - Rotondo, Cinzia
AU  - Rotondo C
AD  - Rheumatology Unit - DIM, School of Medicine, University of Bari, Bari, Italy.
FAU - Praino, Emanuela
AU  - Praino E
AD  - Rheumatology Unit - DIM, School of Medicine, University of Bari, Bari, Italy.
FAU - Nivuori, Mariangela
AU  - Nivuori M
AD  - Rheumatology Unit - DIM, School of Medicine, University of Bari, Bari, Italy.
FAU - di Serio, Francesca
AU  - di Serio F
AD  - U.O. Patologia Clinica 1, Policlinico, Bari, Italy.
FAU - Lapadula, Giovanni
AU  - Lapadula G
AD  - Rheumatology Unit - DIM, School of Medicine, University of Bari, Bari, Italy.
FAU - Iannone, Florenzo
AU  - Iannone F
AUID- ORCID: 0000-0003-0474-5344
AD  - Rheumatology Unit - DIM, School of Medicine, University of Bari, Bari, Italy.
LA  - eng
PT  - Journal Article
DEP - 20150728
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Endothelin Receptor Antagonists)
RN  - 0 (Peptide Fragments)
RN  - 0 (Sulfonamides)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - Q326023R30 (Bosentan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antihypertensive Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Blood Pressure/drug effects
MH  - Bosentan
MH  - Endothelin Receptor Antagonists/*therapeutic use
MH  - Exercise Tolerance/drug effects
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/blood/*drug therapy/etiology/physiopathology
MH  - Longitudinal Studies
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/*blood
MH  - Prospective Studies
MH  - Recovery of Function
MH  - Scleroderma, Systemic/*complications/physiopathology
MH  - Sulfonamides/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Up-Regulation
OTO - NOTNLM
OT  - NYHA
OT  - 6MWT
OT  - DLco
OT  - endothelin-1
OT  - pulmonary arterial pressure
EDAT- 2015/07/29 06:00
MHDA- 2018/03/20 06:00
CRDT- 2015/07/29 06:00
PHST- 2015/07/29 06:00 [pubmed]
PHST- 2018/03/20 06:00 [medline]
PHST- 2015/07/29 06:00 [entrez]
AID - 10.1111/1756-185X.12721 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2017 Jan;20(1):90-96. doi: 10.1111/1756-185X.12721. Epub 2015 
      Jul 28.